Should Pfizer Be Your Next Coronavirus Buy?
The coronavirus pandemic has the world's drugmakers working together to deliver medical solutions and some companies are poised to contribute more than others. With a coronavirus vaccine candidate in late-stage clinical trials and a contract to help manufacture the only COVID-19 antiviral treatment available at the moment, Pfizer (NYSE: PFE) is contributing more than the vast majority of its big pharma peers. Do Pfizer's contributions to the fight against the COVID-19 pandemic make it a good stock to buy right now?
